A recent study conducted within the Translational Research Department, Institut Curie, Universite de Paris, found that in breast cancer patients, "immune infiltration was not determined purely by local tumour microenvironment properties, but was different according to the subtype of the contralateral tumour." The study further unveiled that 5% of patients with bilateral breast cancers carry BRCA1 or BRCA2 mutations; from the 17575 patients listed in the Institut Curie clinical databases, only 2.3% (404) patients had synchronous bilateral breast cancers.
To read more about this study, click here.
Source mentioned: Hamy A-S, Abécassis J, Driouch K, et al. Evolution of synchronous female bilateral breast cancers and response to treatment. Nature Medicine; Published online 6 March 2023. DOI: https://doi.org/10.1038/s41591-023-02216-8
No comments:
Post a Comment